Ye Chuan, Wang Xuemei, Lin Jun, Wu Chenyang, Gao Yuhua, Guo Chenghao, Liao Yunxi, Rao Ziyan, Huang Shaodong, Chen Weixuan, Huang Ying, Sun Jinpeng, Zhao Dongyu, Jiang Changtao
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, 100191, China.
Department of Biomedical Informatics, School of Basic Medical Sciences, Peking University, Beijing, 100191, China.
Sci China Life Sci. 2025 Apr;68(4):1057-1072. doi: 10.1007/s11427-024-2732-8. Epub 2025 Jan 14.
Adipogenesis is the healthy expansion of white adipose tissue (WAT), serving as a compensatory response to maintain metabolic homeostasis in the presence of excess energy in the body. Therefore, the identification of novel regulatory molecules in adipogenesis, specifically membrane receptors such as G protein-coupled receptors (GPCRs), holds significant clinical promise. These receptors can serve as viable targets for pharmaceuticals, offering potential for restoring metabolic homeostasis in individuals with obesity. We utilized trajectory inference methods to analyze three distinct single-nucleus sequencing (sNuc-seq) datasets of adipose tissue and systematically identified GPCRs with the potential to regulate adipogenesis. Through verification in primary adipose progenitor cells (APCs) of mice, we discovered that ADGRD1 promoted the differentiation of APCs, while GPR39 inhibits this process. In the obese mouse model induced by a high-fat diet (HFD), both gain-of-function and loss-of-function studies validated that ADGRD1 promoted adipogenesis, thereby improving metabolic homeostasis, while GPR39 inhibited adipogenesis, leading to metabolic dysfunction. Additionally, through the analysis of 2,400 ChIP-seq data and 1,204 bulk RNA-seq data, we found that the transcription factors (TFs) MEF2D and TCF12 regulated the expression of ADGRD1 and GPR39, respectively. Our study revealed the regulatory role of GPCRs in adipogenesis, providing novel targets for clinical intervention of metabolic dysfunction in obese patients.
脂肪生成是白色脂肪组织(WAT)的健康扩张,是一种补偿性反应,用于在体内能量过剩时维持代谢稳态。因此,鉴定脂肪生成中的新型调节分子,特别是膜受体,如G蛋白偶联受体(GPCRs),具有重大的临床前景。这些受体可作为药物的可行靶点,为恢复肥胖个体的代谢稳态提供潜力。我们利用轨迹推断方法分析了三个不同的脂肪组织单核测序(sNuc-seq)数据集,并系统地鉴定了具有调节脂肪生成潜力的GPCRs。通过在小鼠原代脂肪祖细胞(APC)中的验证,我们发现ADGRD1促进了APC的分化,而GPR39则抑制了这一过程。在高脂饮食(HFD)诱导的肥胖小鼠模型中,功能获得和功能丧失研究均证实,ADGRD1促进脂肪生成,从而改善代谢稳态,而GPR39抑制脂肪生成,导致代谢功能障碍。此外,通过对2400个ChIP-seq数据和1204个批量RNA-seq数据的分析,我们发现转录因子(TFs)MEF2D和TCF12分别调节ADGRD1和GPR39的表达。我们的研究揭示了GPCRs在脂肪生成中的调节作用,为肥胖患者代谢功能障碍的临床干预提供了新的靶点。